Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1–3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma withFGFR3Alterations

医学 转移性尿路上皮癌 高磷血症 内科学 肿瘤科 疾病 化疗 便秘 癌症 癌 膀胱癌 尿路上皮癌 肾脏疾病
作者
Sumanta K. Pal,Jonathan E. Rosenberg,Jean Hoffman‐Censits,Raanan Berger,David I. Quinn,Matthew D. Galsky,Juergen Wolf,Christian Dittrich,Bhumsuk Keam,Jean‐Pierre Delord,Jan H.M. Schellens,Gwénaëlle Gravis,Jacques Médioni,Pablo Maroto,Virote Sriuranpong,Chaiyut Charoentum,Howard A. Burris,Viktor Grünwald,Daniel P. Petrylak,Ulka N. Vaishampayan
出处
期刊:Cancer Discovery [American Association for Cancer Research]
卷期号:8 (7): 812-821 被引量:238
标识
DOI:10.1158/2159-8290.cd-18-0229
摘要

Abstract BGJ398, a potent and selective pan-FGFR antagonist, was prospectively evaluated in patients with metastatic urothelial carcinoma bearing a diverse array of FGFR3 alterations. Patients (N = 67) who were unable to receive platinum chemotherapy were enrolled. The majority (70.1%) had received two or more prior antineoplastic therapies. BGJ398 was administered orally at 125 mg/day on a 3 weeks on, 1 week off schedule until unacceptable toxicity or progression. The primary endpoint was the response rate. Among 67 patients treated, an overall response rate of 25.4% was observed and an additional 38.8% of patients had disease stabilization, translating to a disease control rate of 64.2%. The most common treatment-emergent toxicities were hyperphosphatemia, elevated creatinine, fatigue, constipation, and decreased appetite. Further examination of BGJ398 in this disease setting is warranted. Significance: BJG398 is active in patients with alterations in FGFR3, resulting in both reductions in tumor volume and stabilization of disease. Our data highlight putative mechanisms of resistance to the agent, which may be useful in following disease status. Cancer Discov; 8(7); 812–21. ©2018 AACR. This article is highlighted in the In This Issue feature, p. 781
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
1秒前
Alyssa完成签到,获得积分10
2秒前
2秒前
zsg发布了新的文献求助10
2秒前
清爽的冰淇淋完成签到 ,获得积分10
3秒前
4秒前
Zoe完成签到,获得积分10
4秒前
微笑的应助被SYX采纳,获得10
5秒前
6秒前
YuZhang发布了新的文献求助10
6秒前
6秒前
Toby完成签到,获得积分10
6秒前
离非完成签到 ,获得积分10
7秒前
小情绪发布了新的文献求助10
7秒前
8秒前
8秒前
苹果绿发布了新的文献求助10
9秒前
9秒前
李健的应助被镓氧锌钇铀采纳,获得10
10秒前
11秒前
lhnbnbnb1完成签到,获得积分10
12秒前
Simon发布了新的文献求助10
12秒前
Ren的应助被daomaihu采纳,获得100
13秒前
14秒前
15秒前
小唐发布了新的文献求助10
16秒前
唐兰完成签到 ,获得积分10
16秒前
CipherSage的应助被zsg采纳,获得10
17秒前
17秒前
lb完成签到,获得积分10
17秒前
17秒前
Jasper的应助被SYX采纳,获得10
18秒前
小白完成签到,获得积分10
19秒前
19秒前
Orange的应助被科研通管家采纳,获得10
19秒前
CipherSage的应助被科研通管家采纳,获得10
20秒前
fantasy的应助被科研通管家采纳,获得10
20秒前
20秒前
隐形曼青的应助被科研通管家采纳,获得10
20秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8186750
求助须知:如何正确求助?哪些是违规求助? 9575027
关于积分的说明 21839240
捐赠科研通 7784331
什么是DOI,文献DOI怎么找? 3434808
关于科研通互助平台的介绍 2559206
邀请新用户注册赠送积分活动 2481611